Actinium Pharmaceuticals, Inc.
ATNM
$1.56
-$0.02-1.27%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.97% | 201.76% | 16.83% | 3.59% | -21.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.58% | 73.37% | -28.00% | -12.19% | -20.61% |
| Operating Income | 39.58% | -73.37% | 27.44% | 12.19% | 20.61% |
| Income Before Tax | 39.42% | -83.83% | 28.66% | 12.87% | 25.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.42% | -83.83% | 28.66% | 12.87% | 25.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.42% | -83.83% | 28.66% | 12.87% | 25.22% |
| EBIT | 39.58% | -73.37% | 27.44% | 12.19% | 20.61% |
| EBITDA | 40.31% | -75.17% | 27.57% | 12.38% | 20.76% |
| EPS Basic | 41.53% | -64.33% | 37.28% | 24.11% | 34.87% |
| Normalized Basic EPS | 41.54% | -64.33% | 37.32% | 24.13% | 34.87% |
| EPS Diluted | 41.53% | -64.33% | 37.28% | 24.11% | 34.87% |
| Normalized Diluted EPS | 41.54% | -64.33% | 37.32% | 24.13% | 34.87% |
| Average Basic Shares Outstanding | 3.63% | 11.87% | 13.77% | 14.83% | 14.82% |
| Average Diluted Shares Outstanding | 3.63% | 11.87% | 13.77% | 14.83% | 14.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |